# Vascular and Metabolic Effects of Vytorin

Study · id `cardio:ct-nct01660945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01660945](<https://clinicaltrials.gov/study/NCT01660945>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01660945

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

## Technical summary

Registry record NCT01660945. Randomized; single masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 204 participants (enrolled count; ClinicalTrials.gov record NCT01660945, source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)
- Start date: 2011-07 (registry gives no type) (ClinicalTrials.gov record NCT01660945, source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)
- Primary completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01660945, source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)
- Completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01660945, source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT01660945, source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01660945-2014-11-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Vascular and Metabolic Effects of Vytorin
- Condition: Hypercholesterolemia
- Intervention (Drug): placebo
- Intervention (Drug): vytorin
- Lead sponsor: Gachon University Gil Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Gachon University Gil Medical Center (`cardio:org-gachon-university-gil-medical-center`)

## Provenance

Content hash: 153c196449fb71517c3732349cb23abfcd4030f3660f97eac1bbbfe34946b6a0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
